Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q (Ubiquinol) in Mitochondrial Disorders and Cerebellar Ataxias
2023-505244-18-01Phase 2Withdrawn
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coenzyme q10 in Mitochondriopathy and cerebellar ataxia (CA), sponsored by Fundació Sant Joan de Déu. Primary endpoints: Safety of Ubiquinol and Change in adaptive behaviour (VABS-III). Planned start Nov 2024; status: withdrawn.
02
Drugs
coenzyme q10
03
Conditions
Mitochondriopathycerebellar ataxia (CA)
Beyond the preview
Go deeper on 2023-505244-18-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505244-18-01.